# Semaglutide Effects, Benefits and Safety: What People Report and What the Trials Show > Semaglutide effects in plain English: the benefits and side effects people report (anecdotal), plus the cited safety cautions from the clinical-trial record — appetite, nausea, hair loss, gallbladder and thyroid signals. What the research-use community describes, kept plainly to one side as anecdote, and the cited cautions from the clinical record. ## The short version This page covers two different things side by side. First, what people taking semaglutide say it does — the good and the bad — drawn from patient-review communities. Those reports are honest but anecdotal: they are not controlled data, and your experience may differ. Second, the safety cautions that come from the actual clinical trials and drug-safety reviews, each one cited. The headline benefit people describe is that constant thoughts about food go quiet and appetite drops. The headline downside is stomach upset — nausea, burping, and changes in bowel habits, worst when the dose is first raised. The trial record adds a handful of cautions worth knowing: gallstones, a boxed thyroid-tumor warning carried over from animal studies, muscle-mass loss, and weight regain after stopping. None of this is dosing guidance, and nothing here tells you to start or stop anything. It is a plain summary of semaglutide effects as reported and as studied. ## What people report These are effects reported by the research-use and patient community — **anecdotal, not clinical evidence**, and not verified by controlled trials. They are summarized here without doses and should not be read as findings. **Benefits people describe most often:** - **A quieter relationship with food (frequently reported).** By far the most common benefit people describe is that the constant background chatter about food goes quiet, often within the first week or two. Many say they feel full faster, eat a third to a half of their old portions, and stop thinking about their next meal. A large share call this the single most life-changing effect. - **Fewer cravings (frequently reported).** People repeatedly report that sweet-tooth and sugar cravings drop sharply, and that fried, greasy and high-fat foods stop appealing — sometimes turning slightly off-putting. Several describe naturally drifting toward lighter meals. - **Weight loss (frequently reported).** The large majority of reviewers report losing weight, often describing it as steady and substantial over several months, with the pace slowing after the early period. Many tie it directly to eating much less. - **Better blood-sugar numbers (commonly reported).** Among people using it for type 2 diabetes, a common theme is markedly improved blood-sugar and A1C readings, with some describing fasting numbers dropping into normal ranges. - **Less interest in alcohol (occasionally reported).** A recurring secondary observation is that the urge to drink fades along with food cravings, with some people simply losing interest in drinking. **Downsides people describe most often:** - **Nausea, sometimes with vomiting (frequently reported).** Nausea is the single most reported side effect, mentioned by roughly a third of reviewers, and a subset escalates to vomiting at its worst. It tends to peak in the first weeks and after each dose increase, often easing within a week or two, and flares after overeating or fatty food. - **Sulfur or "egg" burps (commonly reported).** A distinctive complaint is foul-smelling burps people compare to rotten eggs or sulfur, often after a dose increase, sometimes with bloating and a sense of food sitting too long in the stomach. - **Bowel changes (commonly reported).** People report both constipation and diarrhea, sometimes alternating; constipation can be marked, partly because they are eating so little. - **Acid reflux and heartburn (occasionally reported).** Reflux and indigestion come up alongside the burping and bloating and tend to track with dose increases. - **Tiredness early on (commonly reported).** Low energy is common in the first day or two after each injection and during the early weeks, usually easing with time. - **Taste changes and over-suppressed appetite (occasionally reported).** Some report active food aversions, a metallic taste, heightened sensitivity to smells, or appetite so suppressed they must remind themselves to eat. - **Headaches and dizziness (occasionally reported).** Often in the first days of a new dose and frequently linked to not drinking or eating enough; many say hydration helps. - **Injection-site reactions (sometimes reported).** Minor redness, itching, a small bump or tenderness where the dose is given, generally short-lived. ## Semaglutide hair loss Hair shedding is a smaller but recurring report. In patient communities, a subset describe increased shedding, usually noticed a few months in, sometimes alongside a thinner or more hollow-looking face — both widely attributed to losing weight quickly rather than to the drug itself, and the shedding generally described as temporary (anecdotal, not clinical evidence). The research record agrees with that read. A pharmacovigilance disproportionality analysis identified a reporting signal for alopecia (hair loss) with semaglutide and a related medicine [19], and a separate dermatology study linked telogen effluvium — a reversible, diffuse shedding triggered by physiologic stress — to the magnitude and rate of weight loss [20]. The signal is most consistent with rapid-weight-loss-associated telogen effluvium rather than a direct toxic effect on the hair follicle. It is a real reporting signal with a weight-loss-driven explanation, not a confirmed direct drug effect. ## Safety & cautions The cautions below come from the clinical-trial and drug-safety literature, not from anecdote. Each is cited. - **Gastrointestinal intolerance, especially while the dose is raised.** Nausea, vomiting, diarrhea and constipation are the dominant adverse effects in trials and the leading reason people stop. A pooled STEP-program analysis found these events were predominantly mild-to-moderate and transient, concentrated around the titration period [13]; a dedicated safety review reported nausea in roughly one-third of patients [5], and real-world reporting is likewise dominated by gastrointestinal events [14]. This is clinical, not theoretical — the slowing of stomach emptying that causes it is part of how the drug works. - **A personal or family history of medullary thyroid cancer or MEN-2 (boxed warning).** GLP-1 receptor agonists carry a boxed warning for thyroid C-cell tumors, derived from rodents given far-higher-than-human exposures. A 2024 assessment concluded human data do not establish a clear increase in thyroid cancer attributable to semaglutide, so the signal should be read as unconfirmed in humans [15]; nonetheless this family history is treated as a reason not to use the drug, on the strength of the animal finding [5]. - **Acute pancreatitis (class caution).** Pancreatitis is a recognized class warning for this drug family, and treatment is conventionally stopped if it is suspected. The same safety review notes pancreatic-cancer signals remain ones for which firm conclusions cannot yet be drawn given low incidence [5]. The caution is precautionary rather than a demonstrated quantitative risk. - **Gallbladder and gallstone disease.** A dedicated safety review found an increased risk of gallstone disease, attributed largely to the rate and amount of weight loss rather than a direct toxic effect — but the increase versus placebo is a real trial and pharmacovigilance finding, not merely theoretical [5]. - **Pre-existing diabetic eye disease with rapid blood-sugar correction.** In SUSTAIN-6, diabetic-retinopathy complications were significantly more frequent with semaglutide (HR 1.76; 95% CI 1.11-2.78), concentrated in people with existing retinopathy whose blood sugar was lowered quickly [2]. The leading interpretation is early worsening driven by the speed of correction rather than direct eye toxicity; monitoring is advised when glucose is corrected rapidly [5]. - **Loss of lean (muscle) mass.** A STEP-program body-composition substudy reported that the weight lost included both fat and a meaningful proportion of lean mass [16]. Because large, rapid weight loss can erode muscle, this raises a sarcopenia concern — especially in older adults — and has driven research into protein intake and resistance training. The lean-mass loss is an observed trial finding; the downstream muscle-frailty risk is a reasoned extrapolation. - **Weight regain after stopping.** Discontinuation is followed by substantial regain. In the STEP 1 extension, participants regained a mean of roughly 11.6 percentage points of body weight within a year of stopping, and metabolic improvements reverted toward baseline [17]; the STEP 4 withdrawal design showed the same after switching to placebo [9]. This frames the medicine as a long-term rather than a curative one. - **Hair shedding with rapid weight loss.** Covered above: a pharmacovigilance signal for alopecia [19] best explained as weight-loss-associated telogen effluvium, a reversible shedding [20]. - **Pregnancy.** Semaglutide is contraindicated in pregnancy per its labeling. Because its half-life is about a week, with effectively complete clearance only roughly five weeks after the last dose, guidance advises stopping well before a planned pregnancy [21]. The half-life arithmetic that drives the interval is documented; the pregnancy contraindication itself is a regulatory statement. - **The oral form must be taken on an empty stomach.** Oral semaglutide is combined with an absorption enhancer (SNAC) and has very low oral bioavailability (~0.4-1%), so it must be taken fasted with only a little water and kept apart from other food, drink and medicine [22]. Getting this wrong substantially cuts the absorbed amount. This is a formulation requirement, not a toxicity. - **Narrow-margin oral medicines during dose escalation.** A systematic review found the delayed stomach emptying from this drug family generally does not cause clinically significant drug interactions, but advised caution and monitoring for narrow-therapeutic-index oral drugs, especially while the dose is being raised [18]. Overall interaction risk is characterized as low. ## Semaglutide side effects: the trial-record summary Pulling the threads together, the semaglutide side effects established in controlled trials are led by gastrointestinal events — nausea, vomiting, diarrhea, constipation — that are mostly mild-to-moderate, transient, and concentrated during dose escalation [13]. A dedicated safety review places nausea at roughly one-third of patients and adds an increased risk of gallstone disease, with pancreatic and thyroid-cancer signals that remain unconfirmed given low incidence [5]. The diabetic-retinopathy signal seen in SUSTAIN-6 was concentrated in people with existing eye disease undergoing rapid glucose correction [2]. Real-world pharmacovigilance data are consistent: the reporting profile is dominated by gastrointestinal events, with additional signals under ongoing surveillance [14]. None of these figures is a dosing instruction, and none should be read as a personal recommendation. ## Compounded semaglutide Compounded semaglutide is semaglutide prepared by a compounding pharmacy rather than supplied as the approved, manufactured product. It became widely available during a federally declared shortage that ran from roughly 2022 into early 2025, when compounding pharmacies were permitted to produce it. Regulators documented dosing errors, adverse events requiring hospitalization, and products containing unverified or non-pharmaceutical ingredients during that period. After the shortage was declared resolved in early 2025, those compounding pathways were curtailed, leaving ongoing regulatory and telehealth uncertainty. The clinical-trial evidence summarized across this site was generated with the approved manufactured product; compounded or non-pharmaceutical sources fall outside that evidence base and carry their own documented quality and safety concerns. This site sells nothing and is describing the regulatory context, not recommending a source. ## Then and now Semaglutide is the product of decades of incretin-peptide chemistry, built on an earlier GLP-1 medicine and engineered for once-weekly dosing through resistance to the enzyme that normally breaks GLP-1 down and through binding to a blood protein that slows its clearance. It first reached FDA approval for type 2 diabetes in 2017, followed by a daily oral form and, in 2021, a long-term weight-management indication [21]. Its cardiovascular-outcomes evidence read out in SELECT in 2023 [3] and its kidney-outcomes evidence in FLOW in 2024 [6], with a fatty-liver (MASH) indication following in 2025 [12]. During the 2022-2025 shortage, compounding pharmacies were permitted to produce it; that pathway was curtailed once the shortage was declared resolved. --- A measured, fully cited reading of the semaglutide trial record, with the weight-management evidence read first and the open questions kept in plain sight — an editorial digest, not a clinic, a prescriber, or a vendor.